Proficio Capital Partners LLC Makes New $163,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Proficio Capital Partners LLC bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,113 shares of the company’s stock, valued at approximately $163,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Decker Retirement Planning Inc. acquired a new stake in Recursion Pharmaceuticals in the fourth quarter worth approximately $26,000. GAMMA Investing LLC lifted its position in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after acquiring an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the last quarter. KBC Group NV lifted its position in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares during the last quarter. Finally, Colonial River Investments LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $68,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Trading Up 1.8 %

NASDAQ RXRX opened at $6.17 on Thursday. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $12.36. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $2.48 billion, a PE ratio of -4.03 and a beta of 0.85. The firm’s fifty day simple moving average is $7.60 and its 200-day simple moving average is $7.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same period last year, the company posted ($0.42) earnings per share. The company’s revenue was down 57.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on RXRX shares. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.